Enterprise Announces First Timely Topics

The Global HIV Vaccine Enterprise will convene partners from around the world to address two priority issues in HIV vaccine research and development: HIV prevention trials in infants, and vaccine-induced sero-positivity.  Click here to read the full announcement. 

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account